

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
DARREN MARK LE GRAND

INTERNATIONAL APPLICATION NO: PCT/EP2004/010260

FILED: AUGUST 11, 2006

U.S. APPLICATION NO: 10/568,486

FOR: 1,3 DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE
AS CCR-3 RECEPTOR ANTAGONISTS IN THE
TREATMENT OF INFLAMMATORY AND ALLERGIC
DISEASES

MS: Issue Fee
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

In response to the Notice to File Corrected Application Papers sent electronically on July 14, 2010, Applicant submits the following remarks.

Remarks begin on page 2 of this paper.

Remarks

The publication division has requested that Applicant provide serial numbers for attorney docket numbers on page 23, lines 13, 14, and 19-22; page 24, line 2; and page 25, line 7.

Applicant has not made any amendments to the specification because there are no attorney docket numbers on page 23, 24 or 25. At the lines cited by the publication division, Applicant is referring to pharmaceutical compounds which are often described in the literature under code names when a pharmaceutical company has not yet revealed the structure of the compound.

Conclusion

Applicant has addressed the alleged deficiencies cited by the Publication Division. If a communication will expedite issuance of this application, the Division is invited to telephone the undersigned at (617) 871-7802.

Applicant believes that no fees are due. However, if necessary, the Commissioner is hereby authorized to charge payment or credit any overpayment to Deposit Account No. 50-4409 for any fees.

Respectfully submitted,

Novartis Institutes for Biomedical Research
NIBR Patents
220 Massachusetts Ave.
Cambridge, MA 02139
(617) 871-7802


Theresa Devlin
Registration No.: 45,361
Attorney for Applicant

Date: August 10, 2010



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,486	08/11/2006	Darren Mark Le Grand	4-33361A	2308
75074	7590	07/14/2010		
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 220 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139				
			EXAMINER	
			CHUNG, SUSANNAH LEE	
ART UNIT		PAPER NUMBER		
1626				
NOTIFICATION DATE		DELIVERY MODE		
07/14/2010		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

NIBR.MAILDATA@NOVARTIS.COM
PATRICIA.HOFSTETTER@NOVARTIS.COM



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Application No. : 10568486
Applicant : Le Grand
Filing Date : 08/11/2006
Date Mailed : 07/14/2010

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Notice of Allowance Mailed

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

Applicant is given 1 month(s) from the mail date of this Notice within which to respond.

The informalities requiring correction are indicated in the attachment(s). If the informality pertains to the abstract, specification (including claims) or drawings, the informality must be corrected with an amendment in compliance with 37 CFR 1.121 (or, if the application is a reissue application, 37 CFR 1.173). Such an amendment may be filed after payment of the issue fee if limited to correction of informalities noted herein. See Waiver of 37 CFR 1.312 for Documents Required by the Office of Patent Publication, 1280 Off. Gaz. Patent Office 918 (March 23, 2004). In addition, if the informality is not corrected until after payment of the issue fee, for purposes of 35 U.S.C. 154(b)(1)(iv), "all outstanding requirements" will be considered to have been satisfied when the informality has been corrected. A failure to respond within the above-identified time period will result in the application being ABANDONED. **This period for reply is NOT extendable under 37 CFR 1.136(a).**

See attachment(s).

*A copy of this notice **MUST** be returned with the reply. Please address response to
"Mail Stop Issue Fee, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450".*

/Lois Stone/
Publishing Division
Office of Data Management
(571) 272-4200

IDENTIFICATION OF APPLICATION DEFICIENCIES

- ☐ Applicant must provide legible text for the following item(s).
- ☐ Specification filed , page(s) .
 - ☐ Claims filed , claim(s) .
 - ☐ Oath/declaration filed .
 - ☐ Other: .
- ☒ Applicant must provide missing information on the following page(s) of the specification by amending the specification to add the missing text. No new matter may be added.
Page 23, lines 13, 14, 19-22, page 24, line 2, page 25, line 7 - please provide serial numbers for attorney docket numbers..
- ☐ Applicant must provide an Abstract of the Disclosure.
- ☐ Applicant has submitted a DECLARATION (37 CFR 1.63) FOR A UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) (e.g., form PTO/SB/01A). The Application Data Sheet, however, is not present with the filed application. Applicant must submit an Application Data Sheet or file a new oath or declaration (e.g., PTO/SB/01) executed by the inventors and containing the information required in 37 CFR 1.63.
- ☐ Applicant must provide an executed declaration.
- ☐ Applicant must provide a declaration signed by inventor(s) .
- ☐ The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date may be required. See MPEP §§ 602.01 and 602.02. The oath or declaration is defective because:
- ☐ It does not identify the city and either state or foreign country of residence of each inventor. The residence information may be provided on either an application data sheet or a supplemental oath or declaration.
 - ☐ The oath or declaration for the patent application was filed prior to December 1, 1997, and applicant has not given a post office address anywhere in the application papers as required by 37 CFR 1.33(a), which was in effect at the time of filing of the oath or declaration. A statement over applicant's signature providing a complete post office address is required.
 - ☐ It does not identify the mailing address of each inventor. A mailing address is an address at which an inventor customarily receives his or her mail and may be either a home or business address. The mailing address should include the ZIP Code designation. The mailing address may be provided in an application data sheet or a supplemental oath or declaration. See 37 CFR 1.63(c) and 37 CFR 1.76.
- ☐ Per 37 CFR § 1.63(a)(2), applicant must provide at least one given name without abbreviation for inventor(s) .